The Pillar III goal is to support Pillar I and Pillar II efforts by ensuring that U.S. laws, regulations, and policies enable the application of advances in regulatory science to the regulatory review process and adequately support U.S. preparedness for and response to CBRN agents and emerging infectious disease threats with MCMs. 

To do so, FDA is assessing the strengths and weaknesses of the current legal, regulatory, and policy environment regarding MCM development, distribution, administration, and use. Where changes are needed to better protect public health, FDA is working with appropriate partners to develop and propose new approaches.